Lilly launches Foundayo
Eli Lilly has launched Foundayo, a once‑daily oral GLP‑1 weight‑loss pill, and is distributing it through LillyDirect, telehealth providers and pharmacies across the U.S. — a move described as the first small‑molecule pill of its kind and one that broadens access compared with injectable GLP‑1s. Retail platforms like LifeMD and large distributors are already listing the drug, and commentators say the pill plus direct distribution could reshape competitive dynamics in the obesity market. (kffhealthnews.org) (pharmexec.com) (biospace.com)
For the last two years, the biggest weight-loss drugs have mostly come as pens and needles. Eli Lilly just pushed that market in a new direction with Foundayo, a once-daily pill for chronic weight management that the Food and Drug Administration approved on April 1, 2026. (fda.gov) Foundayo’s generic name is orforglipron, and it works by activating the glucagon-like peptide-1 receptor, the same appetite-and-digestion pathway used by injectable drugs like Wegovy and Zepbound. Lilly says adults can take it once a day with or without food. (pi.lilly.com) That “with or without food” detail is one reason this launch is different from earlier oral glucagon-like peptide-1 drugs. Foundayo’s label says there are no food or water timing restrictions, which makes it behave more like a standard daily tablet than a pill built around a strict morning routine. (pi.lilly.com) (drugs.com) The approval itself was unusually fast. The Food and Drug Administration said it cleared Foundayo 50 days after filing, or 294 days before the original January 20, 2027 target date, making it the first new molecular entity approved under the Commissioner’s National Priority Voucher pilot and the fastest approval of a new molecular entity since 2002. (fda.gov) Lilly did not wait around after approval. Its medical information site says prescriptions were accepted immediately after the April 1 decision, with nationwide availability through LillyDirect, United States retail pharmacies, and telehealth channels in early April. (medical.lilly.com) LillyDirect is the company’s own front door for patients, and that changes how the drug reaches people. Instead of relying only on a doctor visit followed by a pharmacy search, Lilly can route patients from online intake to telehealth partners to dispensing in one branded system. (kffhealthnews.org) (medical.lilly.com) Other platforms moved almost immediately. LifeMD said on April 10, 2026 that it had started offering Foundayo to eligible patients through its weight-management program via LillyDirect, adding an oral option alongside injectable glucagon-like peptide-1 treatments. (biospace.com) The label also shows who the drug is for. Foundayo is approved for adults with obesity, or adults who are overweight and have at least one weight-related condition, and it is meant to be used with a reduced-calorie diet and increased physical activity. (foundayo.lilly.com) (pi.lilly.com) The safety profile looks familiar to anyone who has followed this class. Foundayo carries a boxed warning about thyroid C-cell tumors, and the most common side effects in the prescribing information include nausea, vomiting, diarrhea, constipation, indigestion, and gastroesophageal reflux disease. (pi.lilly.com) What Lilly is really testing now is whether convenience can widen the market faster than injections alone did. A daily pill plus direct online distribution gives the company a way to chase patients who wanted the weight-loss effect of glucagon-like peptide-1 drugs but never wanted to learn a weekly shot routine. (kffhealthnews.org) (biospace.com)
